Vir Biotechnology Stock News

Our Motley Fool roundtable likes Intercept Pharma, Viking Therapeutics, and Vir Bio.

In January, amid the omicron surge, WHO's expert panel recommended GlaxoSmithKline Plc GSK / Vir Biotechnology Inc VIR and Eli Lilly And Co's LLY COVID-19 treatments. Get the Inside Access Trad

Vir (VIR), Glaxo's sotrovimab retains neutralizing activity against the BA.2 subvariant of Omicron, per preclinical data.

GlaxoSmithKline (GSK) Vir Biotechnology (VIR) said preclinical data suggested that their COVID-19 therapy sotrovimab retained neutralizing activity against the BA.2 subvariant

LONDON: An antibody-based COVID-19 therapy developed by GSK and Vir Biotechnology retains neutralising activity against the emerging BA.2 form of the Omicron coronavirus variant, Vir said on Thursday, citing data from lab work. The US company said it expected to release preprint data in the coming week, with live virus data to follow. Based on pseudovirus and extensive pharmacokinetic data, the company said it believed the 500 mg dose of sotrovimab is sufficient to retain activity against the BA.2 variant, which is in line with all other variants of concern and interest. The monoclonal antibody therapy, sotrovimab, is authorised for emergency use in the United States. GSK''s COVID-related sales close to $2bn, profit boost to wane in 2022 The companies are sharing the latest data with global regulatory authorities, Vir said. Sotrovimab is one of the few COVID-19 treatments shown to have worked against the fast-spreading Omicron variant, spurring demand. It was amongst GSK''s top selling offerings in 2021.

An antibody-based COVID-19 therapy developed by GSK and Vir Biotechnology retains neutralising activity against the emerging BA.2 form of the Omicron coronavirus variant, Vir said on Thursday, citing pre-clinical data.

Lab studies suggest the antibody treatment, one of the few shown to be effective against omicron, will still be effective against the BA.2 omicron variant, Vir's chief executive said.

GSK racked up 1.4 billion pounds ($1.9 billion) in COVID-related sales in 2021, largely for antibody drug sotrovimab, as it beat quarterly forecasts in its first earnings report since rejecting a bid from Unilever for its consumer arm. The drugmaker also said it expected pandemic-related sales in 2022 to be at similar levels to 2021 but said these would contribute less to profit due to lower margins on its antibody treatment. GSK''s sotrovimab, developed with Vir Biotechnology, is one of the few COVID-19 treatments shown to have worked against the fast-spreading Omicron variant, spurring huge demand. It was amongst GSK''s top selling offerings in 2021. Sales of sotrovimab, or Xevudy, were 828 million pounds in the fourth quarter, up from 114 million in the third quarter and well above market expectations of 774 million pounds. Unilever won''t up £50bn offer for GSK-Pfizer unit Adjusted earnings for the British drugmaker stood at 25.6 pence per share for the three months to Dec. 31, while turnover rose 13% to 9.53 billion pounds at constant currency rates.

The mean of analysts' price targets for Vir Biotechnology, Inc. (VIR) points to a 156.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreemen

Vir Biotechnology (VIR) appointed Johanna Friedl-Naderer as executive vice president and chief business officer, Global, effective March 2, 2022.Prior to joining Vir, Friedl-Naderer

Seasoned Biotech Executive Brings 25 Years Global Commercial Experience to Vir Seasoned Biotech Executive Brings 25 Years Global Commercial Experience to Vir

"Indefensible Edict" - DeSantis Rages After Biden''s FDA Restricts Use Of Monoclonal Antibody Treatments Governor Ron DeSantis is demanding the Biden Administration reverse its sudden decision to revoke emergency use authorization (EUA) for monoclonal antibody treatments. In a statement from the Florida Governor''s office , he rages that this abrupt and unilateral action by the Biden Administration will prevent access to lifesaving treatments for Floridians and Americans. Without a shred of clinical data to support this action, Biden has forced trained medical professionals to choose between treating their patients or breaking the law, said Governor Ron DeSantis. This indefensible edict takes treatment out of the hands of medical professionals and will cost some Americans their lives. There are real-world implications to Bidens medical authoritarianism Americans access to treatments is now subject to the whims of a failing president. Rather than giving Americans the option for various COVID treatments, the FDA and the Biden Administration issued their royal decree, taking away the very thing that is proven to reduce hospitalizations and save lives, said Lieutenant Governor Jeanette Nuñez. Monoclonal antibody treatments like Regeneron have had a positive impact for thousands of Floridians.

GlaxoSmithKline <> and Vir Biotechnology <> are planning to add a second manufacturing facility in the U.S

GlaxoSmithKline and U.S. partner Vir Biotechnology will boost production of their antibody-based COVID-19 treatment by adding a second manufacturing plant to help meet soaring demand in the United Sta

The endemic phase of the outbreak should be a boon for these two biotech stocks.